LP
AKBA icon

LMR Partners’s Akebia Therapeutics AKBA Stock Holding History

LMR Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,678
Closed -$81.8K – 1098
2024
Q1 		$81.8K Buy
+44,678
New +$71.4K ﹤0.01% 937
2022
Q4 		– Sell
-64,849
Closed -$21K – 1096
2022
Q3 		$21K Hold
64,849
– – ﹤0.01% 1157
2022
Q2 		$23K Buy
+64,849
New +$27.2K ﹤0.01% 1226

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

LMR Partners's AKBA Position: Q2 2024 in Review

LMR Partners sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 44,678 shares — an estimated $81.8K sold.

LMR Partners first reported a position in AKBA in Q2 2022 and held it in 3 quarters. The position peaked at $81.8K in Q1 2024. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

  • LMR Partners reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 44,678 Akebia Therapeutics shares in Q2 2024, an estimated $81.8K.
  • LMR Partners first reported a position in Akebia Therapeutics in Q2 2022 and held it in 3 quarters.
  • LMR Partners's Akebia Therapeutics position peaked at $81.8K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.